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from oral lesions and clinical symptoms recorded. The median
age of the 4 females and 2 males was 50.5 years. All patients had
signs of OC with tongue plaques manifesting at a median of 86
days post-HCT (range 30-1045) and symptoms of dry mouth,
anorexia, nausea and/or vomiting. Dysguesia was noted in three
patients and weight loss in ﬁve (median 18 kg). None had
odynophagia and EGD performed in 3 patients was negative for
esophageal candidiasis. A total of 24 isolates were evaluated,
with those tested being resistant to ﬂuconazole, itraconazole,
and voriconazole with respective MIC’s of 256 /ml, 44 /ml
and 14.7 /ml. All isolates were sensitive to amphotericin B
(MIC 0.38 /ml). Concurrent systemic antifungal therapy at the
time of diagnosis of OC comprised: ﬂuconazole, voriconazole,
caspofungin or micafungin, or combination regimens of caspo-
fungin, micafungin, or amphotericin B lipid complex with vori-
conazole. The signs and symptoms persisted despite continua-
tion or alterations in the systemic antifungal regimen. Topical
application to the oral mucosa (5 ml 2-4 times/day) of ampho-
tericin B oral suspension (ABOS), prepared by the pharmacy at
a concentration of 100 mg/ml, resulted in dramatic clinical
response with rapid resolution of symptoms in all 6 patients. OC
relapsed at a median of 65.3 days in all the patients necessitating
re-treatment with ABOS. All patients rapidly responded. We
conclude that ABOS provides a simple, highly effective and
low-cost option for treatment of C. glabrata OC. The use of
newer antifungal agents combined with the incidence and mor-
bidity of other non-albicans OC infections may provide future
directions of study.
HCT Patient Characteristics
Age Sex Diagnosis
Transplant
Characteristics
GI
GvHD
Concurrent
Antifungal
Therapy
39 F CML-BC MRD, Cy/TBI (12
Gy)
Acute FLUC, VORI
51 M MM/PCL MRD, Flu/Mel/Cam Chronic FLUC, VORI
47 F T-ALL/AML MMUD, Cy/TBI/
Cam (12 Gy)
N/A FLUC
60 F DLBCL/NHL MUD, Flu/Mel/Cam Acute VORI, CASP,
MICA
50 F CML-BC MMUD, Flu/TBI/
Cam/CD45 (4.5
Gy)
N/A VORI, CASP,
ABLC, MICA
58 M MDS MRD, Flu/TBI/Cam
(4.5 Gy)
Chronic FLUC, VORI,
CASP, MICA
Abbreviations: CML-BC: Chronic Myelogenous Leukemia in
Blast Crisis; MM/PCL: Multiple Myeloma/ Plasma Cell Leu-
kemia; T-ALL/AML: T-cell Acute Lymphoblastic Leukemia/
Acute Myeloblastic Leukemia; DLBCL/NHL: Diffuse Large
B-cell Lymphoma/Non Hodgkin’s Lymphoma; MDS: Myelo-
dysplastic Syndrome; MRD: Matched Related Donor;
MMUD: Mis-matched Unrelated Donor; MUD: Matched Un-
related Donor; Cy: Cyclophosphamide; TBI: Total Body Irra-
diation; Flu: Fludarabine; Mel: Melphalan; Cam: Alemtu-
zumab; CD45: Investigational Anti-CD45 Monoclonal
Antibody; FLUC: Fluconazole; VORI: Voriconazole; CASP:
Caspofungin; MICA: Micafungin; ABLC: Amphotericin B
Lipid Complex
428
PALONOSETRON FOR THE PREVENTION OF ACUTE AND DELAYED
NAUSEA AND VOMITING FOLLOWING HIGH DOSE MELPHALAN AND
AUTOLOGOUS STEM CELL TRANSPLANTATION
Triﬁlio, S.1, Pi, J.1, Fishman, M.1, Masino, K.1, Kaniecki, K.1,
Mehta, J.1 1Northwestern Memorial Hospital, Chicago, IL.
Recipients of autologous stem cell transplanatation(HSCT) with
high dose melphalan universally experience signiﬁcant acute and
delayed nausea and vomiting(N/V)(60-100%), with the number of
emetic episodes typically increasing over advancing days. Currently
no drugs with FDA approval for delayed N/V have been studied in
recipients of HSCT. Palonosetron, a serotonin antagonist(5HT3)
with a prolonged duration of action, is approved for acute and
delayed onset N/V following moderate to highly emetogenic che-
motherapy. A retrospecive study was undertaken to determine if
the type of 5HT3 used, affected the amount of N/V experienced
and the number of antiemetics used to treat breakthrough N/V.
The treatment group included 25 myeloma patients who received
0.25mg palonsetron prior to HDM followed by HSCT. Melphalan
dose(m2) 200mg(n22),140mg(n2) 100mg(n1). The control
group was comprised of 49 patients who received 24mg IV ondan-
setron prior to HDM. The groups were otherwise compara-
ble.There were no scheduled anti-emetic from day0 onwards, and
anti-emetics were administered “as needed” based on patient needs
as asssessed by nurse clinician or clinical rounds team. As needed
meds includeed lorazepam , prochlorperazine, metoclopramide,
promethazine, ondansetron alone or in combination. Evaluation of
nausea and vomiting was assessed via interview with patient and
review of input/output in medical chart.
Table 1 shows results of palonosetron versus ondansetron and
the use of breakthrough medications. There was a statistically
signiﬁcant reduction in the number of breakthrough medications
needed for both acute and delayed N/V with respect to any break-
though medications(days 1-4) or versus additional ondansetron
only((all 7days). In addition , cost analysis revealed the following-
(all quoted from Redbook 2006): Average daily cost of break-
through medications for palonosetron and ondansetron group 
$14.00 and $56.20 respectively. Average overall cost/patient(in-
cluding prevention) for palonosetron  $477 versus ondanse-
tron.$511. There were no differences in time to engraftment or
signiﬁcnat side effects between groups.
We conclude that the use of palonosetron before HDM prior to
autologous transplantation was more effective that ondansetron in
controlling acute and delayed nausea and vomiting and improving
quality of life. In addition, because of its long duration of action,
palonosetron decreased the need for additional 5HT3 antagonists
leading to overall cost savings.
Breakthrough nausea and vomiting
Day
0-HSCT
Nausea/
Vomiting
(%)
any drug used for breakthrough ondansetron used for breakthrough
Palonosetron
(n25)
Ondansetron
(n49) P-value
Palonosetron
(n25)
Ondansetron
(n49) P-value
0 7/3 30 84 <.001 0 41 <.001
1 48/26 48 78 <.024 4 51 <.001
2 60/7 66 86 <.05 11 59 <.05
3 48/10 48 92 <.001 15 59 <.05
4 55/18 66 90 <.04 11 47 <.01
5 37/7 70 84 ns 15 53 <.006
6 40/25 60 86 <.05 19 47 <.05
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VORICONAZOLE PROPHYLAXIS IN PATIENTS AT HIGH RISK FOR INVA-
SIVE FUNGAL INFECTIONS FOLLOWING ALLOGENEIC HEMATAPOETIC
STEM CELL TRANSPLANTION
Triﬁlio, S.1, Singhal, S.1, Williams, S.1, Winter, J.1, Tallman, M.1,
Gordon, L.1, Evens, A.1, Frankfurt, O.1, Pi, J.1, Mehta, J.1 1North-
western Memorial Hospital, Chicago, IL.
Voriconazole is a triazole antifungal agent with good activity
against Aspergillus spp. Standard antifungal prophylaxis at NMH
for recipients of allogeniec HSCT is itraconazole 200mg po bid.
Voriconazole 200mg po bid is substituted on day0 of transplant if
they have prior history of Aspergillus infection(secondary prophy-
laxis) or switched from itraconazole to voriconazole with receipt of
high dose steroids(methylprednisolone 2mg/kg) for GVHD. Vori-
conazole is discontinued 30 days after immunosuppression is
stopped. 80 allograft recipients who received voriconazole and in
whom complete microbiologic and pharmacokinetic data were
available were studied to determine the efﬁcacy of voriconazole in
preventing invasive fungal infections (IFI). 24 patients had no
itraconazole prophylaxis. The remainder (n56) received itracon-
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azole for 1-161 days (median 7). The length of voriconazole ther-
apy was 6-956 days (median 120). The total number of patient-days
on voriconazole was 14,000d. A total of 10 IFIs were seen in
patients on voriconazole: Candida glabrata (n5), Candida krusei
(n1), Cunninghamella (n1), Rhizopus (n2), and Mucor
(n1).Although 4 cases of zygomycosis were seen, no case of
Aspergillus infection was seen. The actuarial probability of zygo-
mycosis or any invasive fungal infection is 7% and 18% respec-
tively.
Zygomycetes are not susceptible to voriconazole, and break-
through infections are not surprising. In clinical trials C. glabrata
and C. krusei were susceptible to voriconazole at MIC90.5-2mcg
and the majority of ﬂuconazole resistant C.Glabrata isolates have
MIC90s1mcg.dose. Interestingly, steady-state trough voricon-
azole levels were 0.2, 0.2, 0.33, 0.55, 0.63, and 1.78 mcg/mL in
the 6 candidiasis cases. C.Glabrata in patient with vori level1.78
was ﬂuconazole resistant(c/s not avaiable for other Candida spec-
imens). All 6 candidiasis cases were seen amongst the 44 patients
when voriconazole levels  2 mcg and none amongst the 36 with
levels of 2 mcg (P0.061; Fishers exact test), consistent with a
study correlating voriconazole levels and clinical success in as-
pergillosis (Smith et al. Antimicrob Agents Chemother 2006;50:
1570-1572).
Voriconazole is extremely effective in preventing aspergillus in-
fections but Zygomycosis remains a concern in voriconazole-
treated patients. Therapeutic drug monitoring with dose adjust-
ment may be indicated in patients on voriconazole to avoid
infections with fungi that are otherwise susceptible to the drug.
breakthrough infections
Organism Site
Days of
exposure to
voriconazole
Days post
transplant
Concommitant
infection/neutropenia GVHD
Number of
days of prior
exposure to
itraconazole
Voriconazole
level
C.Krusei lung 157 183 E.coli and VRE/no GI 26 0.53
C.Glabrata lung 136 145 VRE/yes GI 9 0.63
C.Glabrata lung 832 837 MRSE/yes GI/Skin 7 0.20
C.Glabrata lung 159 179
MRSA and
Enterobacter/yes GI/Skin 20 1.78
C.Glabrata lung 56 137 MRSA and Strept/yes GI/Skin 122 0.33
C.Glabrata lung 7 9 VRE/yes GI/Skin 7 0.33
Rhizopus sinus 128 135 VRE/no Skin 7 4.1
Rhizopus lung 7 55 none/no none 128 5.9
Mucor lung 77 77 E.coli/no Skin 0 3.5
Cunninghamella lung 17 90 CONS/yes GI 64 1.1
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DISCORDANCE BETWEEN VORICONAZOLE DOSE AND PLASMA CON-
CENTRATIONS: IMPLICATIONS FOR THERAPEUTIC BLOOD MONITOR-
ING
Triﬁlio, S.1, Kamal, K.1, Pennick, G.2, Pi, J.1, Golf, M.1, Mehta, J.1
1Northwestern Memorial Hospital, Chicago, IL; 2University of Texas at
San Antonio, San Antonio, TX.
There is limited data on the effects of drug levels on therapeutic
success in fungal infections. A signiﬁcant correlation between
plasma voriconazole levels(2) and successful Aspergillosis out-
comes was reported.(Smith et al.Antimicob Agents Chemother
2006;(50):1570-2). Pharmacodynamic studies as well as recently
proposed CSLI voriconazole breakpoints suggest a need for ther-
apeutic monitoring. Multiple drugs used during HSCT can affect
the liver cytochrome P450 system, which plays a signiﬁcant role in
voriconazole metabolism. Likewise, voriconazole also exhibits ge-
netic polymorphism. Extensive metabolizers have a signiﬁcantly
lower exposure to voriconazole than poor metabolizers. In a small
trial including 22 patients (Triﬁlio et.al.BMT 2005(5)509) wide
interpatient variablilty in plasma voriconazole levels was reported
for patients receiving equivalent doses of voriconazole, many with
levels below the MIC(90) for Candida and Aspergillus.
In this study, steady-state plasma trough voriconazole levels were
measured after at least 5 days of therapy in 94 patients after HSCT
on 208 separate occassions (median2;range1-5). Most patients
had undergone allogeneic HSCT. Plasma voriconazole levels were
measured using standard HPLC method. The daily voriconazole
dose was 200 mg (n4), 400 mg (n157), 500 mg (n20), 600 mg
(n19), and 800 mg (n8);corresponding to 2.0-16.3 mg/kg (me-
dian 5.4). The voriconazole levels were 0.2-12.5 mcg/mL (me-
dian 1.2). In keeping with the non-linear pharmacokinetic proﬁle
of the drug, a strong correlation was not seen between the dose and
levels.
(P.05)
The table below shows the relationships between levels and dose.
While the amount of drug administered in mg//kg was signiﬁcantly
higher when levels were  5mcg/ml, there was no consistent
relationship between dose and level below that threshold (P val-
ue0.05).
We conclude that adult patients receiving standard doses of
voriconazole have highly variable drug levels. Over 37% of the
voriconazole levels were below the suggested breakpoints for C.G-
labrata and C.Krusei , and over 60% would be associated with a
greater likelihood of failure for Aspergillus infection. Future vori-
conazole studies should include therapeutic drug monitoring, and
until this is clariﬁed, patients should be monitored especially for
those with conﬁrmed life-threatening infections.
Voriconazole levels and dose
Voriconazole
dose/day(mg) n
median
voriconazole
level (range)
average
dose
(mg/kg)
percent of
levels
<0.5mcg
percent of
levels
<1.0mcg
percent of
levels <
2.0mcg
200 4 1.66 (0-3.07) 3.3 25 25 50
400 157 1.09 (0-11.1) 5.2 28 45 65
500 20 1.66 (0-5.99) 6.3 20 40 55
600 19 1.5 (0-6.75) 8.9 21 31 58
800 9 2.06 (0-12.5) 10.8 33 33 50
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